Compare NRT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | FGEN |
|---|---|---|
| Founded | 1975 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.0M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | NRT | FGEN |
|---|---|---|
| Price | $6.25 | $8.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | ★ 63.6K | 28.8K |
| Earning Date | 12-30-2025 | 11-10-2025 |
| Dividend Yield | ★ 12.90% | N/A |
| EPS Growth | ★ 24.05 | N/A |
| EPS | 0.59 | ★ 53.38 |
| Revenue | $6,184,173.00 | ★ $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.59 | ★ $0.16 |
| Revenue Growth | ★ 18.55 | N/A |
| 52 Week Low | $3.88 | $4.85 |
| 52 Week High | $6.95 | $21.94 |
| Indicator | NRT | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 38.23 |
| Support Level | $6.10 | $7.99 |
| Resistance Level | $6.61 | $9.09 |
| Average True Range (ATR) | 0.26 | 0.37 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 66.25 | 34.82 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.